Phaseline

Targets › MULTIPLE

MULTIPLE: drug programs, companies and trials

3 programs from 2 companies in 5 trials: 3 Phase 2, 1 Phase 3, 1 Phase 1; Oncology; next expected readout Feb 2027.

Open in Phaseline: the race on MULTIPLE, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
City of Hope Medical CenterMitomycin
DNA alkylating agent
MULTIPLEPhase 3Metastatic Appendix Carcinoma; Lung Non-Small Cell Carcinoma; Clinical Stage IV Gastric Cancer AJCC v8Oct 2027
Fondazione Policlinico Universitario Agostino Gemelli IRCCSBleomycin
DNA-damaging chemotherapeutic agent used with electrochemotherapy (ECT)
MULTIPLEPhase 2Paget Disease of the VulvaFeb 2027
Fondazione Policlinico Universitario Agostino Gemelli IRCCSCisplatin
Platinum-based DNA-damaging chemotherapeutic agent used with electrochemotherapy (ECT)
MULTIPLEPhase 2Paget Disease of the VulvaFeb 2027

Conditions

Paget Disease of the Vulva (2) Metastatic Appendix Carcinoma (1) Lung Non-Small Cell Carcinoma (1) Clinical Stage IV Gastric Cancer AJCC v8 (1)

Modalities

small molecule (3)

Companies

Fondazione Policlinico Universitario Agostino Gemelli IRCCS (2) City of Hope Medical Center (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.